LBRXLB Pharmaceuticals Inc Common Stock

Shopify downgraded, Five Below upgraded: Wall Street's top analyst calls

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

LB Pharmaceuticals (NASDAQ:LBRX) is seeking to build a “fully integrated company focused on CNS-related diseases,” Chief Executive Officer Heather Turner said during a presentation at a Needham conference hosted by biotech analyst Ami Fadia. Turner said the company’s lead program, LB-102, is a late

NEW YORK (AP) — LB Pharmaceuticals Inc. LBRX) on Thursday reported a loss of $11.5 million in its fourth quarter. On a per-share basis, the New York-based company said it had a loss of 45 cents.

LB Pharmaceuticals (NASDAQ:LBRX) CEO Heather Turner told investors the company is positioned for a series of “clinically meaningful value creating catalysts” following its most recent financing, with multiple late-stage readouts planned for its lead candidate LB-102 across several psychiatric indica

LB Pharmaceuticals (LBRX) announced the initiation of a Phase 2 trial evaluating the efficacy and safety of LB-102 in patients with bipolar depression. LB-102, a novel, once-daily, oral investigational small molecule, is a potent and selective antagonist of D2, D3, and 5HT7 receptors that is being advanced as a potential first benzamide antipsychotic in the U.S. for the treatment of neuropsychiatric disorders. Anna Eramo, Chief Medical Officer of LB Pharmaceuticals added, “We believe LB-102’s ph

NEW YORK (AP) — LB Pharmaceuticals Inc. LBRX) on Thursday reported a loss of $3.6 million in its third quarter. On a per-share basis, the New York-based company said it had a loss of 61 cents.